iBio, Inc.
10-K September 5, 2025
Key Highlights
- Advanced lung fibrosis drug to mid-stage trials
- Launched IBIO-600 and IBIO-610 programs
- AI reduced cancer antibody design time
Read Analysis
🤖 AI Generated
Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.
Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.
Back to Homepage